Menopause
The end of ovarian oestrogen production
What it is
Menopause is defined retrospectively as 12 consecutive months without a period, marking the end of ovarian oestrogen production. The perimenopausal transition preceding it can last years and is often the most symptomatic phase. Common effects include hot flushes and night sweats (vasomotor symptoms), sleep disruption, mood change, brain fog, and genitourinary symptoms such as vaginal dryness and urinary problems. Bone loss accelerates.
Why it matters
Menopause is not a disease, but its symptoms can be genuinely debilitating — and they have an effective treatment. For two decades, women were systematically under-treated because a landmark trial was misread and hormone therapy use collapsed. That was a real and avoidable harm. The evidence now supports hormone therapy as first-line for vasomotor symptoms in most women under 60 or within 10 years of menopause.
What BioSignal knows about treating this
What works for Menopause
BioSignal’s clinical summary, most important first.
- Menopausal hormone therapy — the most effective treatment for vasomotor symptoms
- Low-dose vaginal oestrogen for genitourinary symptoms (minimal systemic absorption; highly effective)
- Non-hormonal options: NK3-receptor antagonists (fezolinetant), SSRIs/SNRIs, gabapentin, CBT
- Resistance training and adequate protein for bone and muscle
- Cardiovascular risk assessment — risk rises after menopause
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Menopausal Hormone TherapyHigh confidence
The most effective treatment for menopausal symptoms. For most women under 60, benefits outweigh risks — and the risks have been overstated for two decades.
- Vitamin DHigh confidence
Effective for deficiency and for bone health in at-risk groups. For broad disease prevention in adults who are already replete, the largest trials are null — and confidence in that null is high. Routine testing of healthy adults is not supported.
- Antidepressants (SSRIs & SNRIs)High confidence
They beat placebo — the evidence is strong. The average effect is modest and grows with severity. The chemical-imbalance explanation was wrong; the medication still works. Withdrawal is real: taper slowly, never abruptly, with your prescriber.
- St John's WortModerate confidence
It genuinely works for mild-to-moderate depression. It also strips other medications of their effect — including the contraceptive pill and immunosuppressants — and must never be combined with an SSRI. Do not take it without telling a clinician what else you take.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Menopause is universal in women — these are factors affecting timing or severity
- Smoking (brings menopause earlier)
- Chemotherapy, radiotherapy, or surgical removal of the ovaries (induced menopause)
- Family history (influences timing)
- Premature ovarian insufficiency (menopause before 40 — a different situation requiring long-term treatment)
How it's diagnosed
In women over 45 with typical symptoms, menopause is a CLINICAL diagnosis — blood tests are not required and FSH can be misleading during the perimenopausal transition, when it fluctuates. Testing has a role in younger women, in suspected premature ovarian insufficiency, and where the picture is unclear.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related body systems
Frequently asked questions
Do I need a blood test to confirm menopause?
If you are over 45 with typical symptoms, no. Menopause is a clinical diagnosis, and FSH can actively mislead during perimenopause because it fluctuates. Testing matters in younger women or where the picture is unclear.
Isn't hormone therapy dangerous?
This is the question two decades of misreporting created, and the answer deserves precision. For most women under 60, or within 10 years of menopause, without contraindications, the benefits of hormone therapy for vasomotor symptoms outweigh the risks, and the absolute risks are small. In the landmark trial's oestrogen-only arm, breast cancer was not increased. The increased risk was seen with combined therapy and grew with duration. Many women have suffered unnecessarily because that nuance was lost.
I just have vaginal dryness. What should I do?
Low-dose vaginal oestrogen is highly effective and produces minimal absorption into the bloodstream, so the concerns attached to systemic hormone therapy largely don't apply. This is one of the most under-treated problems in women's health, and the fear behind that is misplaced.
Evidence summary
Menopausal hormone therapy has strong randomised evidence as the most effective treatment for vasomotor symptoms and for preventing bone loss. The timing hypothesis — that benefit-risk is favourable for women under 60 or within 10 years of menopause — is well supported by reanalysis of the Women's Health Initiative. Vaginal oestrogen is effective for genitourinary symptoms with minimal systemic absorption. Non-hormonal options including NK3-receptor antagonists have randomised support.
References & sources
- The Menopause Society (formerly NAMS) position statement on hormone therapy
- NICE guideline: Menopause — diagnosis and management
- Women's Health Initiative and timing-hypothesis reanalyses
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback